Quadrature Capital Ltd Decreases Stake in Regeneron Pharmaceuticals

Hedge fund reduces holdings in biopharmaceutical company by 13.3% in Q3 2025

Mar. 13, 2026 at 10:52am

Got story updates? Submit your updates here. ›

Quadrature Capital Ltd, a hedge fund, decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% in the third quarter of 2025, according to its most recent 13F filing with the SEC. The fund now owns 61,050 shares of the biopharmaceutical company's stock, valued at approximately $34.31 million.

Why it matters

Regeneron Pharmaceuticals is a major player in the biopharmaceutical industry, known for its innovative drug discovery technologies and pipeline of therapies. Changes in institutional ownership of the company's stock can provide insights into market sentiment and potential future performance.

The details

Quadrature Capital Ltd sold 9,399 shares of Regeneron Pharmaceuticals during the third quarter, reducing its total stake in the company to 61,050 shares. The hedge fund now owns approximately 0.06% of Regeneron's outstanding shares. Other large investors, such as Arrowstreet Capital Limited Partnership and Invesco Ltd., increased their positions in Regeneron during the same period.

  • Quadrature Capital Ltd decreased its holdings in Regeneron Pharmaceuticals in the 3rd quarter of 2025.

The players

Quadrature Capital Ltd

A hedge fund that decreased its stake in Regeneron Pharmaceuticals by 13.3% in the third quarter of 2025.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Quadrature Capital Ltd's stake in Regeneron Pharmaceuticals may signal a shift in market sentiment or portfolio rebalancing, but does not necessarily indicate any broader concerns about the company's fundamentals or future prospects. Investors will likely continue to monitor institutional ownership and other market signals to gauge the outlook for Regeneron's stock.